Clinical Trials List
Protocol NumberCA0881007
Active
2025-05-01 - 2028-02-29
Phase III
Recruiting3
-
Trial Applicant
BRISTOL-MYERS SQUIBB (TAIWAN) LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- 鄭富銘 Division of Hematology & Oncology
- Ching Yun Hsieh Division of Hematology & Oncology
- Chi-Ching Chen Division of Hematology & Oncology
- Che-Hung Lin Division of Hematology & Oncology
- Wei-Ching Lin Division of Hematology & Oncology
- 陳珈妤 Division of Hematology & Oncology
- Ming-Yu Lien Division of Hematology & Oncology
- 王幸婷 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 洪聖祐 Division of Hematology & Oncology
- 邱柏儒 Division of Hematology & Oncology
- 袁章祖 Division of Hematology & Oncology
- 倪紹之 Division of Hematology & Oncology
- 劉家豪 Division of Hematology & Oncology
- 莊佩儒 Division of Hematology & Oncology
- 陳尹愷 Division of Hematology & Oncology
- CHING-CHU LU Division of Hematology & Oncology
- 林耘曲 Division of Hematology & Oncology
- Ming-Che Kuo Division of Hematology & Oncology
- 陳睿哲 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Ming-Che Kuo Division of General Internal Medicine
- Shang-Ju Wu Division of General Internal Medicine
- 范淞斌 Division of General Internal Medicine
- 柯紀綸 Division of General Internal Medicine
- MING YAO Division of General Internal Medicine
- 李思慧 Division of General Internal Medicine
- Wen-Chien Chou Division of General Internal Medicine
- 林耘曲 Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
15 participants
-
Global
440 participants
